Etoposide-Cisplatin Alternating with Vinorelbine-Cisplatin Versus Etoposide-Cisplatin Alone in Patients with Extensive Disease Combined with Small Cell Lung Cancer

Zhang, Jie; Qi, Hui-Wei; Zheng, Hui; Chen, Mo; Zhu, Jun; Xie, Hui-Kang; Ni, Jian; Xu, Jian-Fang; Zhou, Cai-Cun

추천

검색

자료유형: 학술저널

저자정보: Zhang, Jie (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) Qi, Hui-Wei (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) Zheng, Hui (Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine) Chen, Mo (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) Zhu, Jun (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) Xie, Hui-Kang (Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) Ni, Jian (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) Xu, Jian-Fang (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) Zhou, Cai-Cun (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제10호

발행연도: 2014.1

수록면: 4,159 - 4,163 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The aim of this study was to evaluate the efficacy of alternating etoposide-cisplatin and vinorelbine-cisplatin (EP-NP) compared with an etoposide-cisplatin (EP) regimen for advanced combined small cell carcinomas. Materials and Methods: Histologically confirmed combined small cell carcinoma patients who met the inclusion criteria were randomly assigned (1:1) into either the EP-NP setting (group A) or the EP setting (group B). The primary endpoint was progression-free survival in patients who received at least one dose of treatment. Results: Eighty-two patients entered into this trial, 42 in group A and 40 in group B. The objective response rates in group A and group B were 42.9% and 32.5%, respectively (p=0.334). Survival analysis showed that median progression-free survival was 6.1 months in group A, which was significantly longer than the 4.1 months in group B (p=0.041). However, as to overall survival, no significant difference was found between the two groups (11.0 vs 10.1 months in groups A and B, respectively, p=0.545). No unexpected side effects were observed in either group. Conclusions: The EP-NP regimen for combined small cell carcinomas prolonged progressio-nfree survival compared with the EP regimen. Further clinical investigations are warranted.

#Combined small cell lung cancer #chemotherapy #efficacy #etoposide-cisplatin #vinorelbine-cisplatin

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요